Navigation Links
Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment

RARITAN, N.J., Dec. 4 /PRNewswire/ -- Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

Findings from "CNS-Related Comorbidities in Individuals with Self-Reported Epilepsy - Data from the National Survey of Epilepsy, Comorbidities and Health Outcomes" will be detailed in a platform presentation on Dec. 7 at the 2009 American Epilepsy Society (AES) Annual Meeting in Boston. The analysis explores the importance of identifying these Central Nervous System (CNS)-related comorbid conditions, and their potential impact on the clinical management of epilepsy.

The survey results are one of eight presentations supported by Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) at the AES Meeting.

Saturday, Dec. 5: 1-8 p.m. (author presentations 2-3 p.m.)

  • Poster 1.136: "Tolerability of Carisbamate as Adjunctive Treatment of Partial Onset Seizures in Adults in Three Double-blind, Randomized, Placebo-controlled Studies"; M.R. Sperling, E. Faught, J. Schmitt, F. Wiegand, G. Novak
  • Poster 1.134: "Carisbamate as Adjunctive Treatment of Partial Onset Seizures in Adults: Results at 18 Months From an Ongoing Open-label Extension of a Double-blind, Randomized, Dose-ranging Study"; S. Lippmann, W. Rosenfeld, F. Wiegand, J. Schmitt, G. Novak
  • Poster 1.329: "Improving Neurologist-Patient Communication to Promote More Effective Assessment of Side Effects and Comorbidities in Epilepsy: Results of a Phase II Communication Study"; J.M. Stern, D. Labiner, F. Gilliam, P. Penovich, M. Onofrey, C. Eagan, E. Mathis, G.L. Holmes
  • Poster 1.127: "An Open-label Extension of Two Placebo-controlled Studies of Carisbamate as Adjunctive Treatment of Partial Onset Seizures in Adults: 18-month Update"; J. Halford, R. Kalviainen, E. Ben-Menachem, J. Schmitt, F. Wiegand, G. Novak
  • Poster 1.121: "Factors Associated with Time to Discontinuation of Antiepileptic Drug (AED) Treatment In a Commercially-insured Population of Patients with Epilepsy Receiving 2 or 3 AEDs"; J.B. Forlenza, S.S. Johnston, E. Durden, G. Lenhart, S. Ascher, D.M. Biondi, L.A. Costa, G.J. Wan
  • Poster 1.204: "A Drug-Drug Interaction Study of Carisbamate and the Oral Contraceptive, Ortho Tri-Cyclen Lo ®, in Healthy Women"; K. Moore, P. Zannikos, B. Solanki, A. Dibernardo, G. Romano, H.R. Brashear

Sunday, Dec. 6: 8 a.m. - 6 p.m. (author presentations 4-5 p.m.)

  • Poster 2.145: "Health Status Burden in Individuals with Self-Reported Epilepsy from the National Survey of Epilepsy, Comorbidities and Health Outcomes"; J. Cramer, R. Ottman, R.B. Lipton, A.B. Ettinger, M. Yang, M.L. Reed, G.J. Wan

Monday, Dec. 7: Platform Presentations 4-6:15 p.m.

  • Presentation C:05: "CNS-Related Comorbidities in Individuals with Self-Reported Epilepsy from the National Survey of Epilepsy, Comorbidities and Health Outcomes"; R. Ottman, R.B. Lipton, A.B. Ettinger, J.A. Cramer, M.L. Reed, G.J. Wan

About Epilepsy

Epilepsy is one of the most common disorders of the nervous system, affecting more than 50 million people worldwide. As many as 200,000 Americans are diagnosed for the first time each year. Epilepsy produces seizures, which happen when a brief, strong surge of electrical activity affects part or all of the brain. The condition can develop at any time in life, but there is a particular susceptibility in young children and the elderly. Currently, there is no cure for epilepsy; however, medications help control seizure activity in the majority of people with this condition. It is important for people with epilepsy to be proactive in working with their healthcare professionals to determine the most effective treatment plan.

About Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a subsidiary of Johnson & Johnson, provides medicines for an array of health concerns, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; women's health; urology; gastrointestinal disorders; and infectious diseases. The company strives to provide innovative, high-quality, safe and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho-McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Raritan, N.J.

Media Contact:
Tricia Geoghegan
(Onsite at AES) (609) 462-8764
(609) 730-3746

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Looking Older? How Square is Your Jaw Line?
2. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies
5. Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule
6. Staying One Step Ahead of Osteoporosis
7. Combined Pharma Event Visitor Numbers 5% Ahead of 2008 Frankfurt Record
8. CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence
9. Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... , ... The print component of “Supporting Our Caregivers” is ... York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an ... social media strategy and across a network of top news sites and partner ...
Breaking Medicine News(10 mins):